Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis. - Wikidata - wikimedia - TriplyDB

Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

http://www.wikidata.org/entity/Q34062853

about

Silencing SMOC2 ameliorates kidney fibrosis by inhibiting fibroblast to myofibroblast transformation RNA Sequencing Identifies Novel Translational Biomarkers of Kidney Fibrosis.Fibrin deposition following bile duct injury limits fibrosis through an αMβ2-dependent mechanism RNA-binding Protein Musashi Homologue 1 Regulates Kidney Fibrosis by Translational Inhibition of p21 and Numb mRNA.The emerging role of coagulation proteases in kidney disease.A Urinary Fragment of Mucin-1 Subunit α Is a Novel Biomarker Associated With Renal Dysfunction in the General Population.Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker.Application of small RNA sequencing to identify microRNAs in acute kidney injury and fibrosis.Elevated serum fibrinogen level is an independent risk factor for IgA nephropathy.Urinary Fibrinogen as a Predictor of Progression of CKD.Activation of Hepatic Stellate Cells During Liver Carcinogenesis Requires Fibrinogen/Integrin αvβ5 in Zebrafish.Significance of glomerular fibrinogen deposition in children with Henoch-Schönlein purpura nephritis

P2860

Q33578992-91A8B57E-EBA6-41B3-AC1F-A9FFEEEA73B4 Q36944655-715FA704-DA99-4649-A697-C5396903070D Q36965875-C738F1A1-CC38-4698-95E6-EB085C8DFE8E Q37065716-D64FD037-EBBA-4CB7-963E-8ACE1A57662D Q37066587-BE39D262-2DE8-49EB-BD2C-65056E4EDFEF Q41575826-40FBC2F9-2DA4-49E6-BC16-73E5AA227F57 Q43267395-2BD459ED-A112-4D12-B80A-69F6D55AC773 Q46498057-FA35ACFB-3FE1-4278-B1D8-8A097AA01268 Q47100563-9E7A1335-7DC2-4B27-A3CE-188E13BAC830 Q47807294-83AD2320-B5DC-40D8-90B1-0AD7083BB8A4 Q52591520-7AAD9CE1-2915-4A9C-82FB-B3DE52A79135 Q58773866-A0BD7894-5996-4CBD-B97D-FA39A21BA0B7

P2860

Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

http://www.wikidata.org/entity/Q34062853

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

@ast

Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

@en

Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

@nl

type

label

Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

@ast

Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

@en

Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

@nl

prefLabel

Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

@ast

Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

@en

Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

@nl

P1433

Q34062853-BB52FBA7-03CF-4828-985A-2AD7C11F3F01

P1476

Q34062853-6C77C854-ECA4-43FB-88D2-AB039C5FDF92

P2093

Q34062853-32657CD1-5EE4-473B-9383-88A809B81220

Q34062853-4B48E8C9-1096-4A57-B385-8BFEE38E9EA0

Q34062853-4DCE7ED6-5C12-4578-87E6-8FD9B4FF9228

Q34062853-6B3912A9-D242-4270-99C1-E9FF74DB3DE1

Q34062853-75D9DAFE-8037-4821-9131-80845A233FB2

Q34062853-97EA1015-A729-4815-B45A-BF0ED3400A8D

Q34062853-BBD3D29B-9000-48D3-8AC5-099B7818503F

Q34062853-F044BDDB-667C-4EE0-AABE-4F6CD509B243

P2860

Q34062853-0338CA09-5714-450B-A6B3-CABB6647D76C

Q34062853-071C226F-B2A3-4A68-9C36-9CF6930EE72B

Q34062853-0B447862-2F22-4640-A7D0-D8E46B077FC8

Q34062853-0D830902-70BD-49E1-8EDA-A582CE93E748

Q34062853-0F40FE24-7154-4793-BC0B-6CF7AA99DF91

Q34062853-1395A2D1-1203-4D2C-B6B4-F197DB3C9DF3

Q34062853-1F0A798E-A950-4A7D-974A-22B58DCA5E38

Q34062853-27581AA6-10FB-473F-B76A-B832F544CA4C

Q34062853-27CFA48F-B719-4797-B477-581EE1CDC9DB

Q34062853-28E95DE3-88F8-425D-A45D-8330A548CFB1

P304

Q34062853-987CF81B-A3F7-4282-BB67-E4A5BB09A42D

P31

Q34062853-EA941E7D-95FB-4915-9536-557F7B557BBF

P356

Q34062853-71CC1851-EE26-4FDE-BF61-94FA1BA269E4

P433

Q34062853-AF2DADF6-750B-445F-9DCC-F6312DC40B21

P478

Q34062853-6115D6CE-B6F1-457F-84D6-1A1C7EC2C1E0

P577

Q34062853-92642923-E55D-4A6B-B6AA-9B57C242BAC6

P5875

Q34062853-0D0171AC-BFB2-4134-8EF1-9B5D0A34F9F4

P698

Q34062853-2D430CBB-D4CB-41C2-8120-8BEEC3EE5856

P921

Q34062853-AFAAB97A-2B48-48DA-834A-71FBA0F1A625

P932

Q34062853-448EDC05-4661-40CF-9351-A470C03CD3C2

P356

AJPRENAL.00189.2014

P1433

American Journal of Physiology - Renal Physiology

P1476

Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

@en

P2093

Amrendra K Ajay

http://www.w3.org/2001/XMLSchema#string

Benjamin D Humphreys

http://www.w3.org/2001/XMLSchema#string

Dana Hoffmann

http://www.w3.org/2001/XMLSchema#string

Florin L Craciun

http://www.w3.org/2001/XMLSchema#string

Janani Saikumar

http://www.w3.org/2001/XMLSchema#string

Steven L Fabian

http://www.w3.org/2001/XMLSchema#string

Vanesa Bijol

http://www.w3.org/2001/XMLSchema#string

Vishal S Vaidya

http://www.w3.org/2001/XMLSchema#string

P2860

A hepatocyte nuclear factor-3 site in the fibrinogen beta promoter is important for interleukin 6-induced expression, and its activity is influenced by the adjacent -148C/T polymorphism

Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial

Ancrod for the treatment of acute ischemic brain infarction. The Ancrod Stroke Study Investigators

Fibrinogen and fibrin

Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial

Role of the TGF-β/BMP-7/Smad pathways in renal diseases

Fibrinogen β-derived Bβ(15-42) peptide protects against kidney ischemia/reperfusion injury

An inhibitor of thrombin activated fibrinolysis inhibitor (TAFI) can reduce extracellular matrix accumulation in an in vitro model of glucose induced ECM expansion

Prevalence of chronic kidney disease in the United States

Fight-or-flight: murine unilateral ureteral obstruction causes extensive proximal tubular degeneration, collecting duct dilatation, and minimal fibrosis

P304

F471-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPRENAL.00189.2014

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

307

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263816233

http://www.w3.org/2001/XMLSchema#string

P698

25007874

http://www.w3.org/2001/XMLSchema#string

P921

P932

4137131

http://www.w3.org/2001/XMLSchema#string